#USA #Securities Fraud #Howard G. Smith #Unicycive Therapeutics #Bensalem Township

Overview of the Class Action Lawsuit

In a significant development for investors of Unicycive Therapeutics, Inc. (stock symbol: UNCY), the Law Offices of Howard G. Smith announced an opportunity for those who sustained considerable financial losses to potentially lead a class action lawsuit against the company for alleged securities fraud. This important legal action aims to address misleading statements made by the management of Unicycive Therapeutics during a crucial period between December 29, 2025, and June 29, 2026.

Key Allegations

The class action lawsuit claims that Unicycive’s executives made materially false or misleading statements or failed to disclose significant adverse facts regarding the company's business operations and future prospects. Specifically, the allegations highlight the following key points:
1. Manufacturing Compliance Issues: It is asserted that the company did not conduct inspections of its third-party manufacturing vendor’s facilities to ensure compliance with the industry's current good manufacturing practices (cGMP). This oversight raises serious questions about the quality control and safety measures employed by the vendor.
2. Regulatory Risks: The lawsuit indicates that due to the lack of proper audits at the vendor's facility, Unicycive lacked a reasonable basis for asserting that the vendor had adequately addressed previous deficiencies cited by the FDA. Because of this, there was an undisclosed danger that the FDA might require additional data regarding the vendor's manufacturing practices.
3. Delays in Regulatory Approvals: The failure to disclose these critical issues leads to the assertion that the anticipated regulatory approval for OLC (an Unicycive drug candidate) could face substantial delays, which the company’s management had failed to inform investors about.
4. Misleading Investor Communications: Consequently, the lawsuit argues that the positive statements made by management regarding the company’s business and operational outlook were not only misleading but also lacked a solid foundation, leaving investors uninformed about the true risk factors.

Importance of Participation

For shareholders of Unicycive who suffered financial losses, this class action presents a vital opportunity to hold the company accountable. Interested parties are urged to contact the Law Offices of Howard G. Smith by November 2, 2026, to discuss their legal rights and explore the possibility of participating actively in the lawsuit. Investors can reach out via phone at (215) 638-4847 or by email at [email protected]

Next Steps for Investors

To begin the process, investors do not need to take immediate action. They can retain legal counsel of their choice or remain passive members of the class action if they prefer. For those who wish to understand their rights and options in more detail, the Law Offices of Howard G. Smith are available for consultations.

Conclusion

This class action represents a crucial chance for investors of Unicycive Therapeutics to potentially recover losses incurred due to alleged misleading practices by the company's management. As such lawsuits are not just about financial recovery but also about ensuring corporate accountability, the outcome of this case could lead to significant implications for the company's future governance and investor relations. Interested investors are encouraged to take action before the upcoming deadlines to safeguard against further losses.